Herceptin biosimilar market expands with Celltrion-Teva approval
The US regulator has validated Celltrion and Teva’s biosimilar version of Roche’s Herceptin, marking the partnership’s second approval in as many months.
Top Headlines
Global Industry News
-
Roquette buys majority stake in India-based excipient manufacturer
from in-PharmaTechnologist.com
-
Embracing the present and owning the future in clinical trial execution
from Outsourcing-Pharma.com
-
Elpis eyes strategic partnerships as it works to scale ‘direct cell reprogramming’ tech
from Outsourcing-Pharma.com
-
Mallinckrodt plans spin-off biz for generics, APIs, and Amitiza
from in-PharmaTechnologist.com
Hot Topics
-
Outgoing GSK exec shares four industry mega-trends
Emerging Markets
-
European biotech an attractive option for Chinese investment, says VC exec
Pipelines
-
Stable 2019 predicted for pharma despite political and regulatory risk, finds credit agency
Biosimilars
-
Chinese firm plans ‘first-in-class’ biologics after $325m manufacturing investment
Pipelines
